Recent Advances in Anticoagulation Therapy
Anticoagulation
Overview, Rationale, Guidelines and Patient Education
|INSTRINSIC PATHWAY | EXTRINSIC PATHWAY |
Activation by contact with damaged vessel surface Damaged tissues/trauma
[pic]
4.0 Contact Hours
California Board of Registered Nursing CEP#15122
Compiled by Terry Rudd RN, MSN, CCRN
Key Medical Resources, Inc.
6896 Song Sparrow Rd, Corona, Ca 92880
951 520-3116 FAX: 951 739-0378
Disclaimer: This packet is intended to provide information and is not a substitute for any facility policies or procedures or in-class training. Legal information provided here is for information only and is not intended to provide legal advice. Each state or facility may have different training requirements or regulations. Participants who practice the techniques do so voluntarily. Information has been compiled from various internet sources as indicated within the packet. Updated 9/2009
Title: Anticoagulation Overview, Rationale, Guidelines and Patient Education
4.0 C0NTACT HOURS CEP #15122 70% is Passing Score
Please note that C.N.A.s cannot receive continuing education hours for home study.
Key Medical Resources, Inc. 6896 Song Sparrow Rd., Corona, CA 92880
1. Please print or type all information.
2. Complete answers and return answer sheet with evaluation form via fax or email to Key Medical Resources, Inc. Email: Educate100@ FAX: 951 739-0378
Name: ________________________________ Date Completed: ______________ Score____
Email:_____________________________ Cell Phone: ( ) ______________
Certificate will be emailed to you.
Address: _________________________________ City: _________________ Zip: _______
License # & Type: (i.e. RN 555555) _________________Place of Employment: ____________
Please place your answers on this form.
.
1. _____
2. _____
3. _____
4. _____
5. _____
6. _____
7. _____
8. _____
9. _____
10. _____
11. _____
12. _____
13. _____
14. _____
15. _____
16. _____
17. _____
18. _____
19. _____
20. _____
My Signature indicates that I have completed this module on my own._____________________
(Signature)
EVALUATION FORM
Poor Excellent
1. The content of this program was: 1 2 3 4 5 6 7 8 9 10
2. The program was easy to understand: 1 2 3 4 5 6 7 8 9 10
3. The objectives were clear: 1 2 3 4 5 6 7 8 9 10
4. This program applies to my work: 1 2 3 4 5 6 7 8 9 10
5. I learned something from this course: 1 2 3 4 5 6 7 8 9 10
6. Would you recommend this program to others? Yes No
7. The cost of this program was: High OK Low
Other Comments:
Title: Anticoagulation
Overview, Rationale, Guidelines and Patient Education
Self Study Exam 4.0 C0NTACT HOURS
Choose the Single Best Answer for the Following Questions and Place Answers on Form:
1. The end point of the clotting cascade, is:
a. The activation of prothrombin
b. A fibrin clot
c. The activation of prothrombin
d. The inhibition of platelets
2. The clotting factor, prothrombin is factor:
a. II b. IV c. VI d. VIII
3. The lab test to measure the effectiveness of heparin administration is the:
a. Partial thromboplastin time
b. Prothrombin time
c. Platelet count
d. INR
4. Which would be the ideal INR value to help prevent embolism from mechanical heart valves?
a. 1.0 b. 1.5 c. 3.0 d. 4.5
5. The intent of the National Patient Safety Goal, 3E, anticoagulation is to:
a. Reduce the likelihood of harm from anticoagulant therapy.
b. Treat complications of anticoagulant therapy in a timely manner.
c. Assist quality departments with tracking types of complications.
d. Decrease the numbers of patients requiring anticoagulation treatment.
6. Important information to teach your patient about Coumadin (warfarin) includes:
a. Never take a double dose.
b. Carry an ID card or bracelet.
c. Avoid foods with large amounts of vitamin K such as broccoli, spinach or sprouts.
d. All of the above.
7. Instruct your patient to get emergency help for which of the following signs?
a. Blood in the urine. b. Sudden leg or foot pain.
b. Easy bruising or bleeding that will not stop. d. All of the above.
8. Patients who are allergic to __________ should not receive Lovenox.
a. Iodine b. Aspirin c. Strawberries d. Pork
9. When teaching your patient about heparin, you will inform the patient that:
a. The medication has few side effects.
b. Occurrences of bleeding are less than other anticoagulants.
c. The medication will need to be taken every other day.
d. Regular tests of your blood will need to be taken when you are on this medication.
10. Concerns with heparin administration and dosing are which of the following?
a. That there is narrow therapeutic window and complications may occur quickly.
b. Aggressive monitoring needs to done with the drug.
c. The half life is very short.
d. All of the above.
11. The main symptom of heparin toxicity is:
a. Hemorrhage b. Hives c. Abdominal pain d. Muscle aches
12. The Joint Commission has 11 implementation expectations for the NPSG 3E goal. Which guideline is most likely to decrease the problems with heparin dosing?
a. Notifying dietary of the heparin order.
b. Utilization of programmable infusion pumps for IV administration.
c. A baseline INR for the drug.
d. Checking platelet counts routinely.
13. Which lab test is most important to perform for the patient receiving Coumadin (warfarin) therapy?
a. PT b. PTT c. INR d. Platelet count
14. The most commonly prescribed vitamin K antagonist (VKA) is Coumadin (warfarin). If a patient is to have surgery, when should the warfarin be stopped?
a. 4 hours before surgery
b. 8 hours before surgery
c. 5 days before surgery
d. 2 weeks before surgery
15. Which statement is TRUE about the monitoring of Low Molecular Weight Heparins such as Lovenox?
a. Routine monitoring is not recommended as a general rule.
b. INRs are checked weekly.
c. PTTs are checked daily.
d. Platelet counts are monitored monthly.
16. In the future, Rivaroxaban may have significant advantages over warfarin as the drug:
a. Does not require laboratory monitoring.
b. Is dosed once a day.
c. Has no drug-diet interactions.
d. All of the above.
17. On a sample policy for anticoagulation therapy, one important factor to help prevent dosing errors is:
a. Provide each patient with the same dosing.
b. Give medications at the same time each day.
c. Utilized standardized orders and written protocols.
d. Teach only the patient, not the family.
18. Deep vein thrombosis and Pulmonary Embolism prophylaxis orders can help prevent these problems. Low risk patients should receive:
a. Early ambulation
b. Anticoagulation therapy
c. Two pharmacologic agents.
19. Deep vein thrombosis and Pulmonary Embolism prophylaxis orders can help prevent these problems. Patients with a moderate risk for DVT should receive:
a. Early ambulation
b. Anticoagulation therapy
c. Compression stockings
d. All of the above
20. LMWH guidelines suggest:
a. A baseline CBC and BMP b. Routine PTT c. Routine INR
Anticoagulation
Overview, Rationale, Guidelines and Patient Education
4.0 C0NTACT HOURS
Please note that C.N.A.s in California cannot receive continuing education hours for home study.
Objectives
At the completion of the module, the learner will be able to assist and verbalize steps to:
1. Reduce the likelihood of patient harm associated with the use of anticoagulation therapy
2. Discuss High risk treatment
3. Prevent Adverse events
4. Discuss Complexity of dosing, monitoring effects
5. Discuss patient compliance with outpatient therapy
6. Discuss newer drugs that may be utilized in the future for anticoagulation therapy
7. Complete the self-study module at 70% competency
Background and Introduction
The use of anticoagulants can place patients at risk for bleeding. It is important for healthcare personnel to have an understanding of necessary assessments and to identify correct patient education. This module will review the Joint Commission’s National Patient Safety Goal: Requirement 3E, Anticoagulation and provide information that will be helpful for the healthcare provider to prevent risk associated with anticoagulation usage. The information was extracted from multiple internet sites as well has hospital policies and procedures.
Anticoagulation is a high-risk treatment that commonly leads to adverse events due to the complexity of dosing anticoagulation medications, monitoring their effects, and ensuring patient complications with outpatient therapy. The use of standardized practices that include patient involvement can reduce the risk of adverse drug events associated with the use of heparin (unfractionated), Low molecular weight heparin (LMWH), warfarin, and other anticoagulants.
The Failure Mode Effects Analysis (FMEA) is a proactive approach to assessing risk in organizations. Organizations utilizing this model help to identify the processes and data analysis for an effective anticoagulation program. Medical facilities can help with reaching the National Patient Safety Goal for anticoagulation by:
← Implementing a defined anticoagulant management program
← Using ONLY unit dose products and pre-mixed infusions, when these products are available
← When dispensing warfarins dispensed for each patient in accordance with established monitoring procedures
← For patients being started on warfarin, a baseline INR is available
← For patients receiving warfarintherapy, a current INR is available and used to monitor and adjust therapy
← Use approved protocols anticoagulation therapy appropriate to the medication, condition, potential for drug interactions
← Coordinate with dietary services to identify food interactions
← For Heparin, use programmable infusion pumps.
← For Heparin establish baseline and ongoing lab tests.
← Provide patient anticoagulation therapy education for patients, families and healthcare providers
← Provide follow-up monitoring, compliance issues, dietary restrictions, potential for adverse drug reactions and interactions
← Evaluate anticoagulation safety practices
In order to understand anticoagulants, it is important to understand the physiology behind clotting, the diagnostic test, if available for a drug, the monitoring the needs to occur and the expected results for appropriate anticoagulation.
Clotting Cascade
A fibrin clot, the end result of the clotting cascade, is formed by the interplay of the intrinsic, extrinsic, and final common pathways. The intrinsic pathway begins with the activation of factor XII by contact with abnormal surfaces produced by injury. The extrinsic pathway is triggered by trauma, which activates factor VII and releases a lipoprotein, called tissue factor, from blood vessels. Inactive forms of clotting factors are shown as the Roman Numeral; their activated counterparts (indicated by the subscript “a”) Calcium is needed throughout the cascade for clotting to occur. Important to this process is that the activated form of one clotting factor catalyzes the activation of the next factor. The end result is a clot.
|INSTRINSIC PATHWAY | EXTRINSIC PATHWAY |
Activation by contact with damaged vessel surface Damaged tissues/trauma
[pic]
|FACTOR |NAME |SOURCE, FUNCTION, ALTERATION |
|I |Fibrinogen |Manufactured by liver. Decreased in leukemia, livers disease, DIC |
|II |Prothrombin |Produced in liver. Requires Vitamin K for synthesis. Decreased in liver disease, |
| | |Vitamin K deficiency, Drugs - ASA, anticoagulants, antibiotics. |
|III |Thromboplastin |Converts prothrombin to thrombin. Decreased in thrombocytopenia |
|IV |Calcium |Absorbed in GI tract from food. Inorganic ion is required for all stages of |
| | |coagulation. Decreased in malabsorption syndrome, malnutrition, hyperphosphatemia, |
| | |multiple transfusions containing citrate. |
|V |Proaccelerin |Formed by the liver. Accelerates thromboplastin generation and conversion of |
| |(labile factor) |prothrombin to thrombin. Decreased in parahemophilia, liver disease, DIC |
| |AC-Globulin | |
|VI |Not used | |
|VII |Prothrombin conversion |Manufactured in liver and requires vitamin K for synthesis. Anticoagulants depress. |
| |accelerator |Decreased in hepatitis, hepatic CA, Vitamin K deficiency, drugs – anticoagulants, |
| |(stabile factor) |antibiotics |
|VIII |Antihemophilic factor (A) |Required for generation of thromboplastin and conversion of prothrombin to thrombin. |
| | |Sex linked. Decreased in hemophilia A, Von Willebrand’s disease, DIC, multiple |
| | |myeloma, lupus erythmatosus |
|IX |Christmas Factor , Antihemophilic|Manufactured in liver and requires Vitamin K. Essential for generation of |
| |B, plasma thromboplastin |thromboplastin, sex linked. |
| |component (PTC) |Decreased in hemophilia B (Christmas disease), hepatic disease, and Vitamin K |
| | |deficiency. |
|X |Stuart-Prower Factor |Manufactured in liver and requires Vitamin K. helps produce thromboplastin generating|
| | |system. Decreases in liver disease, hemorrhage disease of newborns, DIC, Vitamin K |
| | |deficiency. |
|XI |Thromboplastin Antecedint (PTA) |Essential for plasma-thromboplastin formation. Decreased in hemophilia C, congential |
| |Antihemophilic C |heart disease, intestinal malabsorption of vitamin K, liver disease, anticoagulants. |
|XII |Hageman factor |Activated XII stimulates XI to continue the clotting process. Converts plasminogen to|
| | |plasmin in fibrinolysis. Decreased in liver disease. |
|XIII |Fibrinoligase or fibrin |Fibrinase present in blood, tissue, and platelets and helps to stabilize fibrin |
| |stabilizing factor (FSF) |strands to form a clot. Decreased in agammaglobunemia, myeloma, lead poisoning and |
| | |poor wound healing. |
|Fletcher |Prekallikrein | |
|Fitgerald |High-molecular weight kininogen | |
|Protein C |Xa inhibitor | |
|Protein S | | |
|Roman numeral is factor inactivated, a means activated. |
As you look at the various clotting factors, you can see their names and the sources of these factors. If you notice, Vitamin K is needed for many of the factors. Also, adequate liver functioning is necessary for many of the factors to function properly. In order to assess the efficacy of the clotting cascade, various coagulation tests can help to determine if adequate coagulation, or for that matter anticoagulation is occurring. On the clotting cascade, these values measure the following:
• Prothrombin time measures the extrinsic and common coagulation pathways.
• Partial thromboplastin time measures the instrinsic and common coagulation pathways
• Platelet count assesses platelet concentration
Coagulation studies are done to determine if there is normal or abnormal clotting or the effects of various drugs. If the patient is on Heparin or Courmadin, these values MUST be PROLONGED for adequate anticoagulation to occur. If the person is not on anticoagulants the values are expected to be in the NORMAL range.
|COAGULATION TESTS and Hemostatic Screening Tests |
|Abbreviation |Name |Normal Ranges |Values will |
|aPTT |activated partial thromboplastin time |20 – 30 seconds |Heparin – |
| | | |Increased Time |
|PTT |partial thromboplastin time |26-42 seconds |Heparin – |
| | | |Increased Time |
|PT |Prothrombin time |10.0 – 13.0 seconds |Coumadin – Increased Time |
|INR |International Normalized Ratio |0.8 – 1.3 seconds |Coumadin – Increased Time |
|Platelet Count |150,000 – 400,000 mm3 |150,000 – 400,000 mm3 |Aspirin – decreased |
The INR ratio is international sensitivity index to basically test the effect of the prothrombin time for coumadin effect. The INR helps determine a standardized value that would be best for the type of anticoagulation that is desired. This is the proposed reporting format for the prothrombin time in the patient compared to the prothrombin time in the normal pool. The ISI is international sensitivity index. Recommended therapeutic ranges for INR are:
1. Low intensity anticoagulation 2.0 – 3.0 – treatment and prevention of deep vein thrombosis, prevention of systemic embolism with atrial fibrillation or tissue prosthetic heart valves, prevention of stroke post M.I.
2. Moderate intensity anticoagulation 3.0 – 4.5 – prevention of systemic embolism from mechanical heart valves, reduction of mortality post M.I.
3. Recommended range for oral anticoagulant therapy for INR
a. 2.0 – 3.0 Prophylaxis/tx of venous thrombosis, pulmonary embolism
b. 2.0 – 3.0 Prevention of embolism from atrial fibrillation
c. 2.0 – 3.0 Prevention of embolism from M.I.
d. 2.5– 3.5 Prevention of embolism from mechanical heart valves
e. 2.5 – 3.5 Prevention of embolism from recurrent systemic embolism
Joint Commission Announces 2009 National Patient Safety Goals
The Joint Commission has announced its 2009 National Patient Safety Goals and related requirements for accredited hospitals and critical access hospitals. These Goals apply to the more than 15,000 Joint Commission-accredited and -certified healthcare organizations and programs. The purpose of the National Patient Safety Goals is to improve patient safety. The Goals focus on problems in health care safety and how to solve them. Providing proper care in relation to anticoagulation therapy cross references a number of the 2009 National Patient Safety Goals.
• Identify patients correctly
✓ Use at least two ways to identify patients. For exam- ple, use the patient’s name and date of birth. This is done to make sure that each patient gets the medi- cine and treatment meant for them.
✓ Make sure that the correct patient gets the correct blood type when they get a blood transfusion.
• Improve staff communication
✓ Read back spoken or phone orders to the person who gave the order.
✓ Create a list of abbreviations and symbols that are not to be used.
✓ Quickly get important test results to the right staff per- son.
✓ Create steps for staff to follow when sending patients to the next caregiver. The steps should help staff tell about the patient’s care. Make sure there is time to
✓ ask and answer questions.
• Use medicines safely
✓ Create a list of medicines with names that look alike or sound alike. Update the list every year.
✓ Label all medicines that are not already labeled. For example, medicines in syringes, cups and basins.
✓ Take extra care with patients who take medicines to thin their blood.
• Prevent infection
✓ Use the hand cleaning guidelines from the World Health Organization or Centers for Disease Control and Prevention.
✓ Report death or injury to patients from infections that happen in hospitals.
✓ Use proven guidelines to prevent infections that are difficult to treat.
✓ Use proven guidelines to prevent infection of the
✓ blood.
✓ Use safe practices to treat the part of the body where surgery was done.
• Check patient medicines
✓ Find out what medicines each patient is taking. Make sure that it is OK for the patient to take any new medi- cines with their current medicines.
✓ Give a list of the patient’s medicines to their next caregiver or to their regular doctor before the patient goes home.
✓ Give a list of the patient’s medicines to the patient and their family before they go home. Explain the list.
✓ Some patients may get medicine in small amounts or for a short time. Make sure that it is OK for those patients to take those medicines with their current medicines.
• Prevent patients from falling
✓ Find out which patients are most likely to fall. For example, is the patient taking any medicines that
✓ might make them weak, dizzy or sleepy? Take action to prevent falls for these patients.
• Help patients to be involved in their care
✓ Tell each patient and their family how to report their complaints about safety.
• Identify patient safety risks
✓ Find out which patients are most likely to try to kill themselves.
• Watch patients closely for changes in their health and respond quickly if they need help
✓ Create ways to get help from specially trained staff when a patient’s health appears to get worse.
• Prevent errors in surgery
✓ Create steps for staff to follow so that all documents needed for surgery are on hand before surgery starts.
✓ Mark the part of the body where the surgery will be done. Involve the patient in doing this.
The 2009 Hospital and Critical Access Hospital National Patient Safety Goals (with changes underlined and in bold type) are:
• Reduce the likelihood of patient harm associated with the use of anticoagulation therapy. (Note: This requirement applies only to organizations that provide anticoagulation therapy and/or long-term anticoagulation prophylaxis (for example, atrial fibrillation) where the clinical expectation is that the patient’s laboratory values for coagulation will remain outside normal values. This requirement does not apply to routine situations where short-term prophylactic anticoagulation is used for venous thrombo-embolism prevention (for example, related to procedures or hospitalization) and the clinical expectation is that the patient’s laboratory values for coagulation will remain within, or close to, normal values.)
• When a patient is referred or transferred from one organization to another, the complete and reconciled list of medications is communicated to the next provider of service and the communication is documented. Alternatively, when a patient leaves the organization’s care directly to his or her home, the complete and reconciled list of medications is provided to the patient’s known primary care provider, or the original referring provider, or a known next provider of service. (Note: When the next provider of service is unknown or when no known formal relationship is planned with a next provider, giving the patient, and family as needed, the list of reconciled medications is sufficient.)
• When a patient leaves the organization’s care, a complete and reconciled list of the patient’s medications is provided directly to the patient, and the patient’s family as needed, and the list is explained to the patient and/or family.
• In settings where medications are used minimally, or prescribed for a short duration, modified medication reconciliation processes are performed. (Note: This requirement does not apply to organizations that do not administer medications. However, it is important for healthcare organizations to know what types of medications their patients are taking because these medications could affect the care, treatment, and services provided.)
Encourage patients’ active involvement in their own care as a patient safety strategy.
• Identify the ways in which the patient and his or her family can report concerns about safety and encourage them to do so.
Improve recognition and response to changes in a patient’s condition.
• The organization selects a suitable method that enables healthcare staff members to directly request additional assistance from a specially trained individual(s) when the patient’s condition appears to be worsening.
Patient Safety and Patient Teaching
An Important part of patient safety is teaching. The following pages indicate areas to emphasize with patient teaching with some of the more common anticoagulants such as Coumadin (warfarin), Heparin, and Lovenox (enoxaparin). Your patients and family members may be reading this same information from the internet. It would be good to read this for yourself ahead of time.
Coumadin Patient Information from
Coumadin
Generic Name: warfarin (WAR far in)
Brand Names: Coumadin, Jantoven
What is Coumadin?
Coumadin is an anticoagulant (blood thinner). It reduces the formation of blood clots. It works by blocking the synthesis of certain clotting factors. Without these clotting factors, blood clots are unable to form. Coumadin is used to prevent heart attacks, strokes, and blood clots in veins and arteries. Coumadin may also be used for purposes other than those listed in this medication guide.
Important information about Coumadin
• This medication can cause birth defects in an unborn baby. Do not use if you are pregnant. Use an effective form of birth control, and tell your doctor if you become pregnant during treatment.
• Never take a double dose of Coumadin.
• If you need to have a lumbar puncture (spinal tap) or any type of surgery, you may need to temporarily stop using Coumadin. Be sure the surgeon knows ahead of time that you are using this medication.
• Carry an ID card or wear a medical alert bracelet stating that you are taking Coumadin, in case of emergency. Any doctor, dentist, or emergency medical care provider who treats you should know that you are taking Coumadin.
• Coumadin interacts with many other drugs, and these interactions can be dangerous, even fatal. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.
• You should not take acetaminophen (Tylenol), aspirin, or NSAIDs (non-steroidal anti-inflammatory drugs) unless your doctor has told you to. NSAIDs include celecoxib (Celebrex), diclofenac (Voltaren), ibuprofen (Motrin, Advil), indomethacin, naproxen (Aleve, Naprosyn), piroxicam (Feldene), and others. These medicines may affect blood clotting and could cause serious bleeding in your stomach or intestines.
• Avoid sudden changes in your diet. Vitamin K decreases the effects of Coumadin. Large amounts of vitamin K are found in foods such as liver, broccoli, brussels sprouts, spinach, Swiss chard, coriander, collards, cabbage, and other green leafy vegetables. Do not change the amount of these foods in your diet without first talking to your doctor.
• Avoid eating cranberries, drinking cranberry juice, or taking cranberry herbal products.
• Avoid drinking alcohol, which can increase some of the side effects of Coumadin.
Before taking Coumadin
Do not take this medicine if you have:
• a bleeding disorder such as hemophilia;
• a blood cell disorder such as anemia;
• a stomach ulcer or bleeding in the stomach;
• a history of aneurysm, blood clot, or bleeding in your brain; or an infection of your heart, fluid or swelling around your heart.
FDA pregnancy category X.
Coumadin can cause miscarriage, stillbirth, birth defects, or fatal bleeding in an unborn baby. Do not use Coumadin if you are pregnant. Tell your doctor right away if you become pregnant during treatment. Use an effective form of birth control while you are using this medication.
Before taking Coumadin, tell your doctor if you have:
• kidney disease;
• liver disease;
• celiac sprue (an intestinal disorder);
• a recent injury, surgery, or medical emergency;
• high blood pressure;
• severe or uncontrolled diabetes;
• polycythemia vera;
• congestive heart failure;
• cancer;
• overactive thyroid;
• a seizure disorder for which you take an anticonvulsant such as phenytoin (Dilantin) or phenobarbital (Luminal); or
• a connective tissue disorder such as Marfan Syndrome, Sjogren syndrome, scleroderma, rheumatoid arthritis, or lupus.
If you have any of these conditions, you may not be able to use Coumadin, or you may need a dosage adjustment or special tests during treatment. Coumadin may pass into breast milk and cause bleeding problems in the nursing baby. Do not use Coumadin without telling your doctor if you are breast-feeding a baby. Older adults and people who are severely ill or debilitated may have a greater risk of bleeding while taking Coumadin. Talk with your doctor about your individual risk. Coumadin should not be given to anyone younger than 18 years old. Tell your doctor (or dentist) that you are taking Coumadin before you take an antibiotic or before having surgery.
How should I take Coumadin?
▪ Take this medication exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Your doctor may occasionally change your dose to make sure you get the best results from this medication. Follow the directions on your prescription label.
▪ Take each dose with a full glass of water. Take Coumadin at the same time every day. Coumadin can be taken with or without food.
▪ Your body's response to Coumadin can be affected by your diet, environment, physical well-being, and other medicines or herbal (botanical) products you use.
▪ Avoid dieting to lose weight while taking Coumadin. Tell your doctor if your body weight changes for any reason.
▪ It is important to take Coumadin regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely.
▪ To be sure this medication is helping your condition, your blood will need to be tested on a regular basis. Do not miss any scheduled visits to your doctor.
▪ If you need to have a lumbar puncture (spinal tap) or any type of dental work or surgery, you may need to temporarily stop using Coumadin. Be sure your doctors know ahead of time that you are using this medication.
▪ Carry an ID card or wear a medical alert bracelet stating that you are taking Coumadin, in case of emergency. Any doctor, dentist, or emergency medical care provider who treats you should know that you are taking Coumadin. Store this medication at room temperature away from heat, moisture, and light.
What happens if I miss a dose?
Take the missed dose as soon as you remember, and call your doctor as soon as possible. Do not take two doses at the same time to make up a missed dose.
What happens if I overdose?
Seek emergency medical attention if you think you have used too much of this medicine. Overdose symptoms may include bruising, broken blood vessels under the skin, excessive bleeding from cuts or wounds, blood in the urine or stools, and heavy menstrual periods in women.
What should I avoid while taking Coumadin?
▪ You should not take acetaminophen (Tylenol), aspirin, or NSAIDs (non-steroidal anti-inflammatory drugs) unless your doctor has told you to. NSAIDs include celecoxib (Celebrex), diclofenac (Voltaren), ibuprofen (Motrin, Advil), indomethacin, naproxen (Aleve, Naprosyn), piroxicam (Feldene), and others. These medicines may affect blood clotting and could cause serious bleeding in your stomach or intestines.
▪ Avoid sudden changes in your diet. Vitamin K decreases the effects of Coumadin. Large amounts of vitamin K are found in foods such as liver, broccoli, brussels sprouts, spinach, Swiss chard, coriander, collards, cabbage, and other green leafy vegetables. Do not change the amount of these foods in your diet without first talking to your doctor.
▪ Avoid eating cranberries, drinking cranberry juice, or taking cranberry herbal products.
▪ Avoid drinking alcohol, which can increase some of the side effects of this medication.
▪ Avoid sports or activities that could result in a bruising or bleeding injury. Use extra caution to avoid cuts when brushing your teeth or shaving.
Coumadin side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any of these serious side effects:
• skin changes or discoloration anywhere on your body;
• purple toes or fingers;
• pain in your stomach, back, or sides;
• low fever, loss of appetite, dark urine, jaundice (yellowing of the skin or eyes);
• diarrhea, fever, chills, body aches, flu symptoms;
• easy bruising or bleeding that will not stop;
• blood in your urine;
• black, bloody, or tarry stools;
• nosebleeds, bleeding gums, coughing up blood;
• feeling weak or light-headed;
• sudden headache, confusion, problems with vision, speech, or balance;
• sudden leg or foot pain; or
• sudden numbness or weakness, especially on one side of the body.
Less serious side effects may include: nausea, vomiting, stomach pain, gas and bloating; or hair loss. This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect.
What other drugs will affect Coumadin?
Coumadin interacts with many other drugs, and these interactions can be dangerous, even fatal. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor. Keep a list with you of all the medicines you use and show this list to any doctor or other healthcare provider who treats you.
Coumadin can interact with the following herbal (botanical) products:
|bromelains |danshen |St. John's wort |ginseng |
|coenzyme Q10 |dong quai |ginkgo biloba |garlic |
Do not use any of these products without first asking your doctor. Some of these herbal products can cause you to bleed while you are also taking Coumadin.
Lovenox Patient Information from
Lovenox
Generic Name: enoxaparin (ee nox AP a rin)
Brand Names: Lovenox
What is Lovenox?
▪ Lovenox is a blood thinner, also called anticoagulant (an-tye-koe-AG-yoo-lant). Lovenox prevents the formation of blood clots.
▪ Lovenox is used to prevent blood clots that are sometimes called deep vein thrombosis (DVT), which can lead to blood clots in the lungs. A DVT can occur after certain types of surgery, or in people who are bed-ridden due to a prolonged illness. DVT sometimes occurs suddenly for other reasons.
▪ Lovenox is also used to prevent blood vessel complications in people with certain types of angina (chest pain) or heart attacks called non-Q-wave myocardial infarction or ST-segment elevation myocardial infarction.
▪ Lovenox may also be used for other purposes not listed in this medication guide.
Important information about Lovenox
▪ You should not receive Lovenox if you are allergic to enoxaparin, heparin, or pork products, or if you have any type of major bleeding or a very low blood platelet count.
▪ Before receiving Lovenox, tell your doctor if you are allergic to any drugs, or if you have kidney or liver disease, a heart infection, any bleeding or clotting disorder, high blood pressure, diabetes, a stomach ulcer, an artificial heart valve, or a history of stroke or recent brain or spine surgery.
▪ To be sure Lovenox is helping your condition, your blood will need to be tested often. This will help your doctor determine how long to treat you with Lovenox. Do not miss any scheduled appointments.
▪ You will most likely be treated with other medications such as aspirin or warfarin (Coumadin). To best treat your condition, use all of your medications as directed by your doctor. During your treatment with Lovenox, do not use any other medications unless your doctor tells you to.
If you need to have any type of surgery or dental work, tell the surgeon or dentist ahead of time that you are using Lovenox. You may need to stop using the medicine for a short time, especially if you will be receiving spinal or epidural anesthesia (also called spinal block). This type of anesthesia may increase the risk of paralysis in people who are also using Lovenox.
What should I discuss with my healthcare provider before using Lovenox?
You should not receive this medication if you are allergic to Lovenox, heparin, or pork products, or if you have:
• any type of major bleeding; or
• a very low blood platelet count.
Before receiving Lovenox, tell your doctor if you are allergic to any drugs, or if you have:
• kidney disease;
• liver disease;
• bacterial infection of the lining of your heart;
• a bleeding or blood clotting disorder such as hemophilia;
• uncontrolled or untreated high blood pressure;
• a stomach ulcer;
• eye problems caused by diabetes;
• a history of hemorrhagic stroke;
• a history of low blood platelets caused by receiving heparin;
• if you have recently had surgery on your brain, spine, or eyes;
• if you have an artificial heart valve.
FDA pregnancy category B. Lovenox is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. If you are pregnant, tell your doctor if you have an artificial heart valve. It is not known whether Lovenox passes into breast milk or if it could harm a nursing baby. Do not use Lovenox without telling your doctor if you are breast-feeding a baby.
How is Lovenox given?
▪ Lovenox is given as an injection under the skin, or through a needle placed into a vein. Your doctor, nurse, or other healthcare provider will give you this injection. You may be shown how to inject your medicine at home. Do not self-inject this medicine if you do not fully understand how to give the injection and properly dispose of used needles and syringes.
▪ Do not inject this medication into a muscle.
▪ Your care provider will show you the places on your body where you can safely inject the medication. Lovenox injections under the skin are usually given on the sides of the stomach, alternating between left and right sides. Use a different place in these injection areas each time you use Lovenox. Do not inject into the same place two times in a row.
▪ Lovenox is a clear, colorless liquid. It may appear slightly yellow. Do not use this medicine if it has particles in it. Call your doctor for a new prescription.
▪ Use each disposable needle and syringe only one time. Throw away used needles and syringes in a puncture-proof container (ask your pharmacist where you can get one and how to dispose of it). Keep this container out of the reach of children and pets.
▪ Lovenox may be given for only a couple of days or for up to 2 weeks or longer, depending on the reason you are using it. Follow your doctor's instructions.
▪ To be sure Lovenox is helping your condition, your blood will need to be tested often. This will help your doctor determine how long to treat you with Lovenox. Do not miss any scheduled appointments.
▪ You will most likely be treated with other medications such as aspirin or warfarin (Coumadin). To best treat your condition, use all of your medications as directed by your doctor. Be sure to read the medication guide or patient instructions provided with each of your medications. Do not change your doses or medication schedule without advice from your doctor.
▪ If you need to have any type of surgery or dental work, tell the surgeon or dentist ahead of time that you are using Lovenox. You may need to stop using the medicine for a short time, especially if you will be receiving spinal or epidural anesthesia (also called spinal block). This type of anesthesia can increase the risk of paralysis in people who are also using Lovenox. Store this medicine at room temperature away from moisture and heat.
What happens if I miss a dose?
Use the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to use the medicine and skip the missed dose. Do not use extra medicine to make up the missed dose.
What happens if I overdose?
Seek emergency medical attention if you think you have received too much of this medicine.
Overdose symptoms may cause nosebleeds, blood in your urine or stools, easy bruising or bleeding, or any bleeding that won't stop.
What should I avoid while using Lovenox?
During your treatment with Lovenox, avoid taking aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), or any type of blood thinners unless your doctor tells you to. Using these medications together with enoxaparin can increase your risk of bleeding.
Lovenox side effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Tell your caregivers or call your doctor at once if you have any of these serious side effects:
• bleeding that won't stop;
• pale skin, easy bruising, unusual weakness;
• swelling, bruising, or bleeding where an incision was made during a surgery or other medical procedure;
• sudden numbness or weakness, headache, confusion, problems with vision, speech, or balance;
• pain or swelling in one or both legs; or
• cough, chest pain, trouble breathing; or
• slow heart rate, weak pulse, muscle weakness, tingly feeling.
Less serious Lovenox side effects may include:
• nausea, diarrhea;
a
• swelling in your hands or feet; or
• mild swelling, pain, bruising, or redness where the medicine was injected.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect.
What other drugs will affect Lovenox?
Before you receive Lovenox, tell your doctor about any blood thinners you have been using recently, such as warfarin (Coumadin).
The following drugs can interact with Lovenox. Tell your doctor if you are using any of these:
• sulfinpyrazone (Anturane);
• salicylates such as Novasal, Doan's Extra Strength, Salflex, Tricosal, and others;
• aspirin or other NSAIDs (non-steroidal anti-inflammatory drugs) such as ibuprofen (Motrin, Advil), naproxen (Aleve, Naprosyn), indomethacin (Indocin), ketorolac (Toradol), and others; or
• medication used to prevent blood clots, such as alteplase (Activase), anistreplase (Eminase), clopidogrel (Plavix), dipyridamole (Persantine), streptokinase (Kabikinase, Streptase), ticlopidine (Ticlid), and urokinase (Abbokinase).
This list is not complete and there may be other drugs that can interact with Lovenox. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
Heparin Patient information from
Heparin
Generic Name: heparin (HEP a rin)
Brand Names: Hep-Lock, Hep-Pak CVC, Heparin Lock Flush
What is heparin?
▪ Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. It works by blocking reactions in the body that lead to blood clots.
▪ Heparin is used to treat and prevent blood clots in the veins, arteries, or lungs. It is also used before surgery to reduce the risk of blood clots.
▪ Heparin may also be used for purposes other than those listed here.
Important information about heparin
▪ Before using heparin, tell your doctor if you have high blood pressure, an infection involving your heart, hemophilia or other bleeding disorder, a stomach or intestinal disorder, liver disease, or if you are on your period.
▪ Heparin can cause you to have bleeding episodes while you are using it and for several weeks after you stop. Call your doctor at once if you have easy bruising or unusual bleeding, such as a nosebleed, black or bloody tarry stools, or any bleeding that will not stop. Certain medicines can increase your risk of bleeding while you are using heparin, such as aspirin or other NSAIDs (non-steroidal anti-inflammatory drugs) including ibuprofen (Motrin, Advil), naproxen (Aleve, Naprosyn), diclofenac (Voltaren), diflunisal (Dolobid), etodolac (Lodine), flurbiprofen (Ansaid), indomethacin (Indocin), ketoprofen (Orudis), ketorolac (Toradol), mefenamic acid (Ponstel), meloxicam (Mobic), nabumetone (Relafen), piroxicam (Feldene), and others. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor. Women over 60 years of age may be more likely to have bleeding episodes while using heparin.
Before using heparin
Do not use this medication if you are allergic to heparin, or if you have:
• a severe lack of platelets in your blood; or
• uncontrolled bleeding.
Before using heparin, tell your doctor if you are allergic to any drugs, or if you have:
• an infection of the lining of your heart (also called bacterial endocarditis);
• uncontrolled high blood pressure;
• a bleeding or blood clotting disorder, such as hemophilia;
• a stomach or intestinal disorder;
• liver disease; or
• if you are having a menstrual period.
If you have any of these conditions, you may not be able to use heparin, or you may need a dosage adjustment or special tests during treatment.
FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Heparin does not pass into breast milk. However, do not use this medication without telling your doctor if you are breast-feeding a baby. Women over 60 years of age may be more likely to have bleeding episodes while using heparin.
How should I use heparin?
▪ Heparin is given as an injection into your skin or through a needle placed into a vein. Your doctor, nurse, or other healthcare provider will give you this injection. You may be given instructions on how to use your injections at home.
▪ Heparin must not be injected into a muscle. Do not use this medicine at home if you do not fully understand how to give the injection and properly dispose of needles and other items used in giving the medicine.
▪ Use each needle and syringe only one time. With your medicine you will receive a puncture-proof container for used needles and syringes. If you do not receive a container, ask your pharmacist for one. Keep this container out of the reach of children and pets. Your pharmacist can tell you how to properly dispose of the container.
▪ To be sure this medication is helping your condition, your blood will need to be tested on a regular basis. Your stools may also need to be checked for blood. Do not miss any scheduled visits to your doctor.
▪ Do not use the medication if it has changed colors or has any particles in it. Call your doctor for a new prescription.
▪ You may be switched from injectable heparin to an oral (taken by mouth) blood thinner. Do not stop using the heparin until your doctor tells you to. You may need to use both the injection and the oral forms of heparin for a short time. Store heparin at room temperature away from moisture and heat.
What happens if I miss a dose?
Contact your doctor for instructions if you miss a dose of heparin.
What happens if I overdose?
Seek emergency medical attention if you think you have used too much of this medicine.
Overdose symptoms may include easy bruising, nosebleeds, blood in your urine or stools, black or tarry stools, or any bleeding that will not stop.
What should I avoid while using heparin?
Certain medicines can increase your risk of bleeding while you are using heparin, such as aspirin or other NSAIDs (non-steroidal anti-inflammatory drugs) including ibuprofen (Motrin, Advil), naproxen (Aleve, Naprosyn), diclofenac (Voltaren), diflunisal (Dolobid), etodolac (Lodine), flurbiprofen (Ansaid), indomethacin (Indocin), ketoprofen (Orudis), ketorolac (Toradol), mefenamic acid (Ponstel), meloxicam (Mobic), nabumetone (Relafen), piroxicam (Feldene), and others.
What are the possible side effects of heparin?
▪ Heparin can cause you to have bleeding episodes while you are using it and for several weeks after you stop. Call your doctor at once if you have easy bruising or unusual bleeding, such as a nosebleed, blood in your urine or stools, black or tarry stools, or any bleeding that will not stop. Get emergency medical help if you have any of these signs of an allergic reaction: nausea, vomiting, sweating, hives, itching, trouble breathing, swelling of your face, lips, tongue, or throat, or feeling like you might pass out.
▪ Some people receiving a heparin injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel nauseated, light-headed, sweaty, or short of breath during or after a heparin injection.
▪ Stop using heparin and call your doctor at once if you have any of these serious side effects:
• sudden numbness or weakness, especially on one side of the body;
• sudden headache, confusion, problems with vision, speech, or balance;
• pain or swelling in one or both legs;
• trouble breathing; or
• fever, chills, runny nose, or watery eyes.
Less serious side effects may include:
• mild pain, redness, warmth, or skin changes where the medicine was injected;
• mild itching of your feet; or
• bluish-colored skin.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.
What other drugs will affect heparin?
Before using heparin, tell your doctor if you are using any of the following drugs:
• another blood thinner, such as warfarin (Coumadin);
• salicylates such as aspirin, Disalcid, Doans Pills, Dolobid, Salflex, Tricosal, and others;
• dipyridamole (Persantine);
• nicotine cigarettes, gum, lozenges, or skin patches;
• cold, allergy, or sleep medications (Allerest, Benadryl, Chlor-Trimeton, Dimetapp, Sominex, and others);
• hydroxychloroquine (Plaquenil, Quineprox);
• digoxin (digitalis, Lanoxin, Lanoxicaps); or
• demeclocycline (Declomycin), doxycycline (Adoxa, Doryx, Oracea, Vibramycin), minocycline (Dynacin, Minocin, Solodyn, Vectrin), or tetracycline (Brodspec, Panmycin, Sumycin, Tetracap).
If you are using any of these drugs, you may not be able to use heparin, or you may need dosage adjustments or special tests during treatment.
This list is not complete and there may be other drugs that can interact with heparin. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.
Where can I get more information?
• Your pharmacist can provide more information about heparin.
What does my medication look like?
• Heparin is available with a prescription as an injection under the name heparin. Ask your pharmacist any questions you have about this medication, especially if it is new to you.
The following pages list articles found on the internet related to anticoagulants. The full articles are cited with the web site listing. Summaries of the article information are provided for your review.
Current Issues in Heparin Dosing
Summarized from
Joanna M. Pangilinan, PharmD, BCOP Medscape Pharmacists. 2007; ©2007 Medscape Posted 07/31/2007
[pic]
Unfractionated heparin (UFH) is a widely used anticoagulant, commonly given for prophylaxis and treatment of thrombotic disorders including venous and pulmonary embolism. About half of all patients with acute venous thromboembolism (VTE) are treated with UFH, despite alternatives such as low-molecular-weight heparin (LMWH).[1] Because UFH has a narrow therapeutic window and may cause bleeding complications, aggressive monitoring is necessary to ensure efficacy and patient safety. For these reasons, the Institute for Safe Medication Practices (ISMP) placed heparin on a list of high-alert medications.[2] This article will review key points in heparin dosing and monitoring for the adult patient; clinical scenarios will address issues in heparin dosing.
The half-life of UFH is also dose-dependent and may range from 30 to 90 minutes or more in patients receiving high doses.[3] Heparin clearance consists of a rapid saturable phase and slower first-order process. In the saturable phase, endothelial cells and macrophages bind with heparin, eliminating it from the circulation. Renal elimination constitutes most of the nonsaturable phase. Therefore, a disproportionate anticoagulant response may occur at therapeutic doses with the duration and intensity of anticoagulation rising nonlinearly with increasing dose.[4]
Heparin Toxicity
The main toxicity of heparin is hemorrhage, which can cause serious morbidity and mortality. Major bleeding occurred in 4% of VTE patients receiving UFH who were evaluated in routine clinical practice.[5] Table 1 lists factors that may increase bleeding risk associated with UFH. Treatment of severe bleeding may require supportive care, transfusion, or the antiheparin agent protamine.[4]
Heparin-induced thrombocytopenia type 2 (HIT) is a thrombocytopenia of 50% or more during treatment with a heparin product. HIT occurs in up to 5% of patients receiving a heparin product, usually 5-10 days after heparin initiation. The major sequelae of HIT are development of serious venous or arterial thrombosis or both. When this occurs, immediate discontinuation of UFH/LMWH is prudent, and an alternative anticoagulant must be started.[6]
In addition, heparin-induced osteopenia may occur as a result of long-term heparin anticoagulation. The cause may be suppressed osteoblastic bone formation and activated osteoclastic bone resorption.[7]
Heparin Dosing
Various patient factors may affect response to heparin as well. In an evaluation of patients with acute coronary syndromes, longer activated partial thromboplastin times (aPTTs) were associated with weight < 70 kg, age 65 years and older, female sex, and black race; shorter aPTTs were associated with diabetes and smoking.[10] The clinician may consider such factors when dosing UFH.
Heparin Monitoring
Heparin is usually monitored according to the aPTT, a measure of activity of fibrinogen, prothrombin, and factors V, VIII, IX, X, XI, and XII, as well as heparin inhibition of these factors.[11] The aPTT is affected by biologic variables (eg, patient comorbidities, hemostatic defects), preanalytic variables (eg, timing of aPTT blood sample, sample storage), and analytic variables (eg, reagent sensitivity, laboratory methods).[11]
The general use of a fixed aPTT range is not recommended.[4] The ACCP and the American College of Pathologists recommend that the therapeutic aPTT range be calibrated for each reagent lot/coagulometer by determining the aPTT values that coincide with therapeutic heparin levels.[4,12] For VTE treatment, the recommended antifactor Xa activity range is 0.3-0.7 IU/mL. While the range for coronary indications is uncertain, the upper range is likely 0.6 IU/mL.[4]
The aPTT should be drawn 6 hours after initiation of UFH and 6 hours after each dose adjustment. The aPTT can be drawn every 24 hours after 2 consecutive aPTTs are therapeutic, with dosage adjustment if necessary.[9]
Conclusion
UFH continues to be a cornerstone of treatment for a range of indications requiring anticoagulation. Careful dosing and monitoring are necessary to reduce the risk for patient harm and to maximize the therapeutic benefit. The clinician should refer to UFH guidelines whenever possible to assist in dosing and monitoring of this complex medication.
[pic]
Table 1. Factors That May Increase Bleeding Risk in UFH Use[4]
|Dose |
|Coadministration of thrombolytic |
|Coadministration of glycoprotein IIb/IIIa inhibitor |
|Recent surgery, trauma, or invasive procedure |
|Concurrent hemostatic defects |
Table 2. UFH Dosing for Special Patient Groups[4]
|Indication | |Recommended Dosage |
|VTEa |Venous thromboembolism |80 units/kg bolus; 18 units/kg/h infusion |
|ACSb |Acute coronary syndromes |60-70 units/kg bolus (max 5000 units); 12-15 units/kg/h|
| | |(max 1000 units/h) infusion |
|Acute STEMIc with |ST segment elevated Myocardial infarction with recombinant |60 units/kg bolus (max 4000 units); 12 units/kg/h (max |
|rtPAd |tissue plasminogen activator |1000 units/h) infusion |
Table 3. Potential Causes of Heparin Resistance[4]
|Antithrombin deficiency |
|Increased heparin clearance |
|Increased number of heparin-binding proteins |
|Increased factor VIII levels |
|Increased fibrinogen levels |
|Drug-induced resistance |
Recent Advances in Anticoagulation Therapy
Release Date: November 7, 2008;
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on . These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2008 Medscape.
Recent Advances in Anticoagulation Therapy
As printed in Medscape online. A module available at no charge at
by Jill M. Strykowski, MSc, RPh
Anticoagulation Therapy in the Spotlight
Anticoagulation therapy in the acute care setting has been the focus of considerable attention on 2 fronts: clinical practice and process improvement. New regulatory requirements, updated consensus guidelines, and strong evidence supporting novel therapies all contribute to improvements in the safe delivery of antithrombotic therapy. From monitoring and dispensing anticoagulation agents to clinical decision making, new evidence will guide clinical practice and influence how anticoagulation therapy is delivered to patients with or at risk of thromboembolic disease.
The antithrombotic class of medications is prominent on the list of high-risk, high-alert medications published by the Institute for Safe Medication Practices (ISMP), indicating that errors involving these agents can result in more significant harm to patients.[1] High-risk, high-alert medications warrant heightened attention to safe medication management practices.
For the 18,000 hospitals accredited by The Joint Commission (TJC) nationally, special management of high-risk medications is required. TJC's Medication Management Standards are designed to assist healthcare organizations in improving medication safety and quality of care. TJC's prescriptive medication management standard 7.10 requires hospitals to develop processes for procuring, storing, ordering, transcribing, preparing, dispensing, administering, and monitoring high-risk, high-alert agents.[2] In spite of these mandatory safety strategies, however, adverse events and patient harm associated with anticoagulation therapy continue to occur.
The risks associated with anticoagulation therapy are well known and were highlighted recently in several well-publicized, high-profile medical errors. The most recent event involved a pharmacy in Corpus Christi, Texas, where an error in mixing heparin reportedly caused the death of infant twins. In a related case in Los Angeles in 2007, actor Dennis Quaid's newborn twins were given heparin in a dose that was 1000 times the normal dose; the twins barely survived. Quaid has publicly criticized the drug manufacturer because of the look-alike packaging of 2 different strengths of heparin. In September 2006, 6 babies in Indiana received the same overdose of heparin that the Quaid twins received, and 3 of those infants died. In response, the ISMP published causative factors for heparin errors and corresponding safety strategies in the July 17, 2008 Medication Safety Alert.[3] A clear recommendation was extended to hospitals to conduct a Failure Mode and Effects Analysis on their neonatal heparin medication management processes.
In addition to these dispensing and mixing errors, recent product withdrawals were prompted by adulterated heparin. As many as 81 deaths have been linked to a Chinese-manufactured contaminant, oversulfated chondroitin sulfate. This animal-cartilage-derived contaminant mimics heparin for a fraction of the cost and is the probable cause of serious allergic reactions and deaths following its use. As a result of the product withdrawals, most organizations have had to buy heparin in unfamiliar packaging and concentrations, increasing the risk of error.
MEDMARX, an Internet accessible program operated by the US Pharmacopeia, is used by healthcare facilities to report and track medication errors and adverse drug reactions. According to MEDMARX data from January 2003 through December 2007, the highest frequency of medication errors (33.4%) occurred with anticoagulant medications such as heparin.[4] The majority (47.6%) of heparin errors occurred at the bedside, 14.1% during prescribing, 13.9% in the dispensing process, and 18.8% during transcribing and documenting.
According to the Institute for Healthcare Improvement (IHI), heparin ranks third in reports of product errors associated with harm, followed by warfarin (ranked sixth), and low-molecular-weight heparin (ninth ). A recent review by Kanjanarat and colleagues[5] reported that anticoagulation therapy was associated with serious and frequent adverse events in both the inpatient and outpatient settings. As a result of all these safety issues, IHI has called for specific changes in managing anticoagulants.[6] Recommendations include using standard protocols, involving patients, consulting dietary professionals, and providing adequate monitoring.
Clearly, the scope of the problem is considerable, and TJC is paying special attention. Anticoagulant therapy is prone to adverse events as a consequence of the complexity of dosing, monitoring of effects, and ensuring patient compliance. The risk of harm related to anticoagulant errors is so great that a subgoal of TJC's National Patient Safety Goal (NPSG) 3 -- improve the safety of using medications -- is devoted solely to anticoagulation therapy.
National Patient Safety Goal 3E
NPSG 3E, "Reduce the likelihood of harm associated with anticoagulation therapy," is slated for implementation by January 1, 2009. To ensure that this occurs on schedule, TJC has required organizations to meet 4 milestones during a year-long phase-in period in 2008[7] (Table 1). Daryl Rich, Pharm D, a surveyor for TJC, addressed this issue at a meeting of the American Society of Health-System Pharmacy (ASHP) in June 2008. He affirmed that if organizations are to be surveyed by TJC in 2008, the achievement of these milestones will need to be apparent to the surveyor. "We will be looking for a plan," warned Dr. Rich.[8]
Table 1. NPSG 3E Milestones
|Milestone Completion Date |
|The organization's leadership has assigned responsibility for oversight and coordination April 1, 2008 of the development, testing, and |
|implementation of NPSG requirement 3e |
|An implementation work plan is in place that identifies adequate resources, assigns accountabilities, and a timeline for full July 1, 2008|
|implementation of NPSG 3e by January 1, 2009 |
|Pilot testing in at least 1 clinical unit is underway October 1, 2008 |
|The process is fully implemented across the organization January 1, 2009 |
Appended to NPSG 3E are 11 implementation expectations detailing key points of the medication management process with which organizations must comply (Table 2). Achieving NPSG 3E will require standardized practices as well as the involvement of patients. Organizations are currently developing policies and procedures to improve and track nearly every aspect of anticoagulation therapy from dispensing of pre-mixed, unit-dosed products to education of nurses, physicians, pharmacists, and ancillary staff.
Table 2. The Joint Commission's 11 Implementation Expectations for NPSG 3E
|1. The organization implements a defined anticoagulant management program to individualize the care provided to each patient receiving |
|anticoagulant therapy. |
|2. To reduce compounding and labeling errors, the organization uses ONLY oral unit dose products and premixed infusions, when these |
|products are available. |
|3. When pharmacy services are provided by the organization, warfarin is dispensed for each patient in accordance with established |
|monitoring procedures. |
|4. The organization uses approved protocols for the initiation and maintenance of anticoagulation therapy appropriate to the medication |
|used, to the condition being treated, and to the potential for drug interactions. |
|5. For patients being started on warfarin, a baseline International Normalized Ratio (INR) is available, and for all patients receiving |
|warfarin therapy, a current INR is available and is used to monitor and adjust therapy. |
|6. When dietary services are provided by the organization, the service is notified of all patients receiving warfarin and responds |
|according to its established food/drug interaction program. |
|7. When heparin is administered intravenously and continuously, the organization uses programmable infusion pumps. |
|8. The organization has a policy that addresses baseline and ongoing laboratory tests that are required for heparin and |
|low-molecular-weight heparin therapies. |
|9. The organization provides education regarding anticoagulation therapy to prescribers, staff, patients, and families. |
|10. Patient/family education includes the importance of follow-up monitoring, compliance issues, dietary restrictions, and potential for |
|adverse drug reactions and interactions. |
|11. The organization evaluates anticoagulation safety practices. |
Goal 3E and associated implementation expectations apply only to therapeutic doses of low-molecular-weight heparin (LMWH), unfractionated heparin (UFH) and warfarin. TJC has clarified that "if it is usual practice for patients to be kept on therapeutic ranges of anticoagulant for several days as a prophylactic strategy then NPSG 3E is applied."[9] Further, TJC stipulates that this goal "only applies to patients receiving these drugs for therapeutic purposes and not for flushes, etc." Finally, TJC states that even though the goal applies to the 3 specified products, it does not preclude organizations from including other agents such as direct thrombin inhibitors in their anticoagulation management programs.
Both compliance and TJC's intentions were addressed at the ASHP meeting by Edith Nutescu, PharmD, FCCP, Clinical Associate Professor of Pharmacy Practice, University of Illinois.[10] According to Dr. Nutescu, a policy and procedure addressing the implementation expectations should be developed by hospitals, and all staff must be educated on the elements of the policy. Further, the policy must address lab tests and the requirement for a baseline international normalized ratio (INR) prior to dispensing warfarin. Consideration should be given to using "double checks" as a risk reduction strategy. One of the institutions involved in a neonatal heparin error described above later implemented a nursing double check as a risk reduction strategy. Additionally, Dr. Nutescu emphasized that organizations must have a formalized anticoagulant education program for both staff and patients, and that unit-dose and premixed infusions are used when available.
Hospital pharmacists are becoming increasingly involved in the dosing of anticoagulant therapy. Management complexities, agent choices, and special patient population assessments have prompted clinicians to rely on the expertise of clinical pharmacists.[11] A recent study demonstrated that the risk reduction strategy of pharmacist involvement in initiating and managing warfarin therapy improved the safety of anticoagulation therapy. When managed collaboratively, thrombotic events declined from 4.6% to 0%.[11] Undoubtedly, the NPSG 3E will encourage even greater utilization of clinical pharmacist monitoring. Support and tools for inpatient program development were recently published by the ASHP.[12] This guide assists organizations in meeting NPSG 3E through a step-by-step process, covering topics such as administrative support and the pharmacology of anticoagulant agents.
NPSG 3E aims to reduce the harm associated with anticoagulation therapy through a systematic approach. A robust anticoagulation program for LMWH, UFH, and warfarin that encompasses multiple stages of the medication management process requires education for all staff, involves the patient, and is closely monitored, will undoubtedly lead to a decline in adverse events. The regulatory and safety work must be coupled with a keen eye toward new evidence that should be integrated into standard practices.
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
A standardized approach can serve as a safety net for anticoagulation management, but what is the clinical evidence that guides decision making? In June 2008, the American College of Chest Physicians (ACCP) published the eighth edition of consensus guidelines, Antithrombotic and Thrombolytic Therapy,[13] updating the previous edition with evidence published between 2002 and 2006. These guidelines are widely viewed as a treatise for evidence-based management.
In their critical review of the literature, guideline authors followed a strict methodology for evaluating the evidence related to the management of thromboembolic disorders. Clinical questions provided the framework for the literature review. The data from published studies related to these clinical questions were the foundation for the development of treatment recommendations. Clinical recommendations were then graded with a numbering scheme based on the trade-off between benefits, risks, burden, and cost, and the level of confidence in estimating benefits and risks. Each recommendation was given 1 of 2 grades corresponding to the strength of the author's recommendation, either strong (grade 1) or weak (grade 2).[14] For treatment recommendations assigned a grade of 1, desirable effects were much greater than undesirable effects (or vice versa) and benefits outweighed harms, burdens, and costs. For grade 2 recommendations, desirable effects were not clearly greater or less great than the undesirable effects, and the magnitude of risks, burdens, and costs were less certain.[14]
Furthermore, the quality of the evidence upon which the recommendations were based was scored A, B, or C for high, moderate, or low quality evidence, respectively. Each recommendation was assigned an overall score such as 1A or 2C so the practicing clinician would be able to make patient care decisions based on the strength of the evidence and recommendation. A 1A grade, for example, is a widely adopted practice that should become standard across all hospitals, and is the safest strategy for the treatment of thromboembolic disease. It should be noted that the authors use the verb "recommend" for items with grade 1 (strong) evidence, and "suggest" for items with grade 2 (weaker) evidence.[14]
Clinical guidelines have substantial implications not only for health, but also for allocation of healthcare resources -- the trade-off of "money for health."[15] It is feasible to incorporate resource considerations into clinical guidelines.[15] Therefore, in addition to grading the strength and methodology of studies, some of the recommendations were supplemented with an underlying value assessment based on patient preferences, patient values, and cost. When resource allocation is an issue, the recommendations state the sensitivity to that underlying value assessment.
For example, recommendation 3.1, under the clinical question related to perioperative management of patients who are receiving bridging anticoagulation, reads:
"In patients who require temporary interruption of VKAs [Vitamin K Antagonists] and are to receive bridging anticoagulation, from a cost-containment perspective we recommend the use of SC LMWH administered in an outpatient setting where feasible instead of inpatient administration of IV UFH (Grade 1C)."
The corresponding value assessment and preferences are:
"This recommendation reflects a consideration not only of the trade-off between the advantages and disadvantages of SC LMWH and IV UFH as reflected in their effects on clinical outcomes (LMWH at least as good, possibly better), but also the implications in terms of resource use (costs) in a representative group of countries (substantially less resource use with LMWH)."[16]
Value assessments allow clinical decisions to be broadly evidence-based, yet take value into account when resources are critical to decision making.
Several of the ACCP guidelines are directly relevant to the implementation of NPSG 3E in the hospital setting. Highlights of guidelines for Pharmacology and Management of Vitamin K Antagonists (VKA),[17] Perioperative Management of Antithrombotic Therapy,[18] and Parenteral Anticoagulants [19] will be summarized here, along with important differences from the seventh edition of the guidelines.
Vitamin K Antagonists
Warfarin is the single most common vitamin K antagonist (VKA) in clinical practice and is also the most commonly prescribed oral anticoagulant. Key points in the guidelines related to VKA:
• Therapy should be initiated at a dose of 5-10 mg for the first 1-2 days in most patients. The INR response should guide subsequent dosing, and should begin after the first 2-3 doses (Grade 1B). The eighth edition includes the first mention of an evidence-based assessment of pharmacogenetic-based dosing. Until randomized data are available, the authors do not recommend this practice (grade 2C);
• Initial dosing should be ≤ 5 mg in persons who are elderly, debilitated, malnourished, have congestive heart failure, have hepatic disease, have had recent surgery, or have drug-drug interactions known to affect the response to warfarin (grade 1C).The recommendation for lower VKA dosing in persons with recent surgery or known drug-drug interactions is new in the eighth edition;
• For the use of vitamin K in response to a mild to moderately elevated INR with minimal bleeding, oral rather than subcutaneous vitamin K should be used (grade 1A). This recommendation is unchanged from the seventh edition. For significant bleeding with an elevated INR, the recommended route of vitamin K reversal is slow IV infusion (grade 1C); and
• Finally, the authors advise that optimal management of VKA employs many elements of the NPSG 3E requirements: systematic and coordinated management, patient education, tracking, follow-up, and good patient communication. Although the evidence relates primarily to the outpatient setting, the guidance reflects best practice for in-patients as well.
Perioperative Management of Antithrombotic Therapy
• Regarding the interruption of therapy in the perioperative setting, the need for bridge therapy and anticoagulant choice are based on the patient's thromboembolic risk. New with the eighth edition is a chapter that addresses the management of surgical patients who require bridge therapy;
• VKAs should be stopped 5 days before surgery to allow for INR normalization (grade 1B);
• VKAs should be resumed 12-24 hours postoperatively to allow for adequate hemostasis (grade 1C);
• In patients with mechanical heart valves, atrial fibrillation, or venous thromboembolism (VTE) at high risk for thromboembolism, bridging anticoagulation with therapeutic doses of LMWH or intravenous (IV) UFH is recommended (grade 2C). There is evidence of a preference for subcutaneous (SC) LMWH over IV UFH (grade 2C). In similar patients with moderate risk of thromboembolism, the authors suggest therapeutic dosing of LMWH, IV UFH, or low-dose SC LMWH (grade 2C) with a preference for SC LMWH (grade 2C). Finally, in patients with mechanical heart valves, atrial fibrillation, or VTE at low risk for thromboembolism, the authors suggest either bridge therapy with low-dose SC LMWH or no bridging (grade 2C);
• Recommendations regarding the timing of preoperative and postoperative anticoagulants are more prescriptive in the eighth edition than in the 2004 edition. The most recent evidence supports stopping LMWH 24 hours before surgery, and using half the total daily dose for the last preoperative dose (grade 1C). In patients receiving bridge therapy with IV UFH, the recommendation is to stop UFH 4 hours prior to surgery (grade 1C); and
• Postoperatively, for minor surgical or other invasive procedures, the recommendation is to resume LMWH 24 hours after the procedure when there is adequate hemostasis (grade 1C). For major surgery with high risk of bleeding when therapeutic LMWH/UFH is planned, the recommendation is to delay LMWH/UFH for 48 to 72 hours following surgery, administering low-dose LMWH/UFH after surgery when hemostasis is secured, or completely avoiding LMWH or UFH after surgery (grade 1C).
Parenteral Anticoagulants
In addition to their use in bridging anticoagulant therapy in the perioperative setting, parenteral anticoagulants are widely used for a variety of indications. Both the LMWHs and fondaparinux (Arixtra®, GlaxoSmithKline) are favored for their more predictable pharmacokinetics and pharmacodynamics as well as convenient dosing, especially in the outpatient setting. In many cases, these drugs have replaced UFH. However, despite being convenient to use, they carry a high risk for bleeding. The ACCP offers the following guidelines regarding the use of parental anticoagulants:
• Routine monitoring of LMWH is not recommended unless the patient is pregnant and being treated with therapeutic doses (grade 1C);
• Routine coagulation monitoring for fondaparinux is not recommended. The anti-Xa level can be used to monitor anticoagulant activity as long as the drug is used as a reference standard in the assay; and
• Recommendations for dosing LMWH in special populations are given. Obese patients treated with either prophylactic or therapeutic doses of LMWH should receive weight-based dosing (grade 2C). Patients with renal insufficiency (creatinine clearance < 30 mL/min) should receive UFH instead of LMWH. If it is necessary to use LMWH in this population, the dose should be reduced to 50% of the recommended dose (grade 2C).
Promising New Oral Therapies for Thromboprophylaxis
Warfarin is an effective, but difficult to use medication. After more than 50 years of experience with warfarin, the addition of an easy-to-use oral anticoagulant to the armamentarium is a welcome advance for patients at risk for thromboembolism. Many drugs have been in development over the past 10 years. In 2004, the US Food and Drug Administration (FDA) denied approval of ximelagatran, a potential competitor to warfarin, because it was linked to elevated liver enzyme levels in 8% of patients and 3 deaths from an aggressive form of hepatitis.
Since that time, several drugs have been in the clinical trial stage of development. Among them are dabigatran (Pradaxa®, Boehringer Ingelheim) and rivaroxaban (Xarelto®, Bayer HealthCare and Johnson & Johnson).
Dabigatran
Dabigatran, a direct thrombin inhibitor, is similar to ximelagatran in that it is the prodrug of the orally bioavailable dabigatran etexilate.[20] Dabigatran binds directly to thrombin and prevents the cleavage of fibrinogen to fibrin, an essential step in thrombus formation. Dabigatran inhibits both fibrin-bound thrombin as well as circulating fibrin. The plasma half-life of single dose dabigatran is 8 hours and for multiple doses, 17 hours, allowing for once-daily dosing.[21] There is evidence in patients with renal insufficiency (creatinine clearance < 50 mL/min) that excretion may be prolonged, suggesting that dose adjustments may be necessary.
Laboratory monitoring of dabigatran with INR is not indicated. There is a linear relationship between plasma concentrations of dabigataran and anticoagulant effect measured by ecarin clotting time and thrombin time ; however, these tests have not been widely used in association with dabigataran therapy.[22]
Dabigatran has shown promise in recent phase III trials. In fact, the drug received an approval recommendation from the European Committee for Medicinal Products in Human Use (CHMP) and is now approved in all 27 European Union member states for use in thromboprophylaxis following total hip and total knee replacement surgeries. Health Canada has also recently announce the approval of dabigatran, based on the findings of the RE-NOVATE, RE-MODEL, and RE-MOBILIZE randomized controlled trials.[23-25]
The first major phase III trial that led to the recent approvals was the RE-NOVATE trial. In this study, 3494 patients undergoing total hip replacement were randomized to 28-35 days of dabigatran 220 mg once a day, dabigataran 150 mg once a day, or enoxaparin 40 mg SC once a day. This trial succeeded in demonstrating non-inferiority to enoxaparin along with an equivalent safety profile (Table 3).[24]
Table 3. RE-NOVATE Trial Outcomes
|Outcome Variable |Dabigatran 220 mg Daily (%) |Dabigatran 150 mg Daily (%) |Enoxaparin 40 mg Subcutaneous Daily (%) |
|Primary outcome* (total VTE or |6.0 |8.6 |6.7 |
|death) | | | |
|Safety outcome (major bleeding) |2.0 |1.3 |1.6 |
*Primary outcome variable included venographic or symptomatic evidence of VTE
In the RE-MODEL phase III trial, 2076 patients undergoing total knee replacement surgery were randomized to either oral dabigatran etexilate 220 mg once daily, oral dabigatran 150 mg once daily, or enoxaparin 40 mg subcutaneous once daily for a treatment duration of 6-10 days. Patients were observed for up to 3 months. Again, the prespecified noninferiority criteria were met for the primary outcome variable and there was no difference in the incidence of bleeding events (Table 4). In addition, there was no difference in hepatic enzyme elevation or cardiovascular events during the 3-month follow-up period.[23]
Table 4. RE-MODEL Trial Outcomes
|Outcome Variable |Dabigatran 220 mg Daily (%) |Dabigatran 150 mg Daily (%) |Enoxaparin 40 mg Subcutaneous Daily (%) |
|Primary outcome* (total VTE or |36.4% |40.5% |37.7% |
|death) | | | |
|Safety outcome (major bleeding) |1.5% |1.3% |1.3% |
*Primary outcome variable included venographic or symptomatic evidence of VTE
The RE-MOBILIZE trial was similar to the RE-MODEL trial in that the sample was composed of patients undergoing total knee arthroplasty. The main difference was the dose of enoxaparin, which was 30 mg subcutaneous twice daily rather than 40 mg once daily.[26] Notwithstanding these similarities, the efficacy of dabigatran in the RE-MOBILIZE trial was found to be inferior to twice-daily enoxaparin (Table 5). The incidence of the primary outcome variable (total VTE or all-cause mortality) was significantly higher in patients receiving dabigatran. The lack of positive endpoints was due to the higher incidence of asymptomatic VTE detected during protocol-directed venography at the end of the trial. The incidence of actual VTE events was similar across all groups and the incidence of major bleeding events was likewise not significantly different.
Table 5. RE-MOBILIZE Trial Outcomes
|Outcome Variable |Dabigatran 220 mg Daily (%) |Dabigatran 150 mg Daily (%) |Enoxaparin 30 mg Subcutaneous Twice Daily (%) |
|Primary outcome* (total VTE or |31.1 |33.7 |25.3 |
|death) | | | |
|Major VTE |3.4 |3.0 |2.2 |
|Safety outcome (major bleeding) |0.6 |0.6 |1.4 |
Phase III trials involving different patient groups are ongoing. The RE-COVER trial (2550 patients) and the RE-MEDY trial (2000 patients) compare dabigatran with warfarin for treatment and secondary prevention of symptomatic venous thromboembolic disease; these studies are expected to conclude in 2009.[27] The RE-LY trial compares dabigatran with warfarin in the prevention of stroke and systemic embolism. In January of this year, enrollment closed after more than 18,000 patients with atrial fibrillation were evaluated. These results are also expected in 2009.
Rivaroxaban
Rivaroxaban offers significant management advantages over warfarin. It does not require laboratory monitoring, is dosed once a day, and to date, no drug-drug or drug-diet interactions have been identified. Nor is rovaroxaban associated with the same adverse hepatic effects that were the demise of ximlelagatran 4 years ago. The advantages of rivaroxaban are related to the drug's high selectivity for factor Xa. An L-shaped structure enables inhibition of free factor Xa, prothrombinase activity, and clot-associated factor Xa, encouraging the breakdown of clots and prevention of new clot formation. Furthermore, by not directly inhibiting thrombin activity, rivaroxaban allows traces of thrombin to escape neutralization, thus facilitating hemostasis and leading to a favorable safety profile with respect to bleeding.[28] Maximum inhibition of factor Xa occurs within 1-4 hours following administration. Rivaroxaban has a half-life of approximately 9 hours, allowing for nearly 24 hours of factor Xa inhibition.
Testing with rivaroxaban has produced positive results in 3 recent phase III clinical trials in patients undergoing hip and knee arthroplasty. Newly published results support previous work demonstrating that rivaroxaban is significantly more effective than enoxaparin with no differences in the incidence of bleeding in total knee and total hip arthroplasty patients.[29]
The latest published evidence comes from the RECORD 1, 2, and 3 phase III trials. These studies also evaluated rivaroxaban versus enoxaparin in thromboprophylaxis. In all cases, rivaroxaban demonstrated superior efficacy to enoxparin for postoperative venous thromboembolic (VTE) disease prevention with similar rates of bleeding.[30,31] Recently presented at the European Federation of the National Association of Orthopedics and Traumatology, RECORD 4 trial results were similar to those of the previous RECORD trials.[32] There was a 31% reduction in relative risk of the primary outcome variable with no statistically significant increase in bleeding.
Notable in the RECORD series is the RECORD 2 study, which is the largest trial to date that measures anticoagulation efficacy post-hospital stay. Data from RECORD 2 demonstrate convincing evidence that prolonged treatment for up to 5 weeks substantially decreases the risk of VTE. Until now, long-term anticoagulant treatment has created numerous management issues, such as the need for laboratory monitoring with warfarin and prolonged injections with LMWHs. For RECORD trials 1-4, the primary efficacy outcomes and safety outcomes are shown in Table 6.
Table 6. RECORD 1-4 Trial Outcomes
|Trial |Population |Rivaroxaban |Enoxaparin |DVT/PE/Death |RRR |Any on-treatment |Safety Outcome |
| | |(PO) |(SQ) |Primary outcome |(%) |bleeding- no. *(%)|P Value |
| | | | | | |Safety outcome | |
| | | | | | | | |
| |9 |9 |9 |9 |9 |9 |9 |
|Dabigatran | | | | | | | |
|etexilate | | | | | | | |
| | | | | | | | |
| | | | | | | | |
|Low molecular | | | | | | | |
|weight heparin | |9 |9 |9 |9 |9 | |
|(LMWH) | | | | | | | |
| | | | | | | | |
| | | | | | | |9 |
|Warfarin |9 | | | | | | |
*Heparin-induced thrombocytopenia (HIT) is thrombocytopaenia (low platelet counts) due to the administration of
heparin
GENERIC NAME: Rivaroxaban (BAY 59-7939)
The following was written by Gretchen Kunze, Doctor of Pharmacy Candidate at the University of Colorado at Denver and Health Sciences Center. It is written in the form that would be used if a hospital were to consider adding it to their formulary (a list of medications used in that hospital). It is current as of October 27, 2007.
PROPRIETY NAME: Xarelto® (Bayer HealthCare, Ortho-McNeil Pharmaceuticals Inc.)
THERAPUETIC CLASS: Oral Anticoagulant
SIMILAR DRUGS: Warfarin, Enoxaparin
INDICATIONS: Rivaroxaban is currently in Phase III clinical trials and does not have any approved indications at this time. However, Bayer HealthCare, intends to submit for approval for indications in stroke prevention in atrial fibrillation and in the treatment and long-term secondary prevention of venous thromboembolism (VTE). They are also studying the effectiveness of this drug in the management of acute coronary syndrome (ACS).8, 1
Table 1: Comparison of FDA-Approved Indications for Anticoagulants
|Drug |Trade Name |Company |FDA-Approved Indications |
|Rivaroxaban |Xarelto® |Bayer, Ortho-McNeil |None at this time |
|Warfarin |Coumadin® |Many |Prophylaxis and treatment of thromboembolism in PE, VTE, |
| |Jantoven® | |post-MI, prosthetic cardiac valves, and A. Fib. |
|Enoxaparin |Lovenox® |Sanofi-Aventis |Prophylaxis and treatment of DVT, prophylaxis of post-op DVT|
| | | |(hip, knee, abdominal), unstable angina or non-Q-wave MI |
Table 2: Comparison of the Pharmacokinetic Parameters of Available Anticoagulants
| |Rivaroxaban |Enoxaparin |Warfarin |
|Onset of action |2.5-4 hours |3-5 hours |36-72 hours |
|Duration of action |24 hrs |12 hrs |2-5 days |
|Bioavailability |60-80% | 92% |100% |
|Metabolism |Unknown |Hepatic |Hepatic, metabolites |
|Elimination t ½ |5.7-9.2 hours |4.5-7 hours |20-60 hours |
|Protein binding | |80% |~ 99% |
|Renal excretion |66% |40%, 10% unchanged |92% |
|Biliary excretion |28% |60% |8% |
|Dose adjustment in renal |N/A |YES |NO |
|dysfunction | | | |
|Dose adjustment in hepatic |N/A |NO |YES |
|dysfunction | | | |
GENERIC NAME: dabigatran
The following was written by Adrienne Light, Doctor of Pharmacy Candidate at the University of Colorado at Denver and Health Sciences Center. It is written in the form that would be used if a hospital were to consider adding it to their formulary (a list of medications used in that hospital). It is current as of October 27, 2007.
Table 1: Comparison of FDA-Approved Indications for anticoagulant therapy: 1,2
|Drug |Trade Name |Company |FDA-Approved Indication |Date of FDA |
| | | | |Approval |
|Warfarin |Coumadin |Bristol Myers |Treatment of DVT or Pulmonary Embolism |1954 |
| | |Squibb Co |DVT prophylaxis | |
| | | |Arterial thromboembolism prophylaxis with mechanical prosthetic heart| |
| | | |valves | |
| | | |Cardioembolic stroke prophylaxis in atrial fibrillation | |
| | | |Stroke prophylaxis with history of non-cardioembolic ischemic stroke | |
| | | |Coronary artery thrombosis prophylaxis post-MI | |
|Enoxaparin |Lovenox |Sanofi-Aventis |Venous thromboembolism treatment |1993 |
| | |U.S. |DVT prophylaxis | |
| | | |Acute Coronary Syndromes treatment | |
|Dabigatran |Rendix |Boehringer-Ingelhe|None currently |Target of 2010 |
| | |im U.S. | | |
Table 2: Comparison of the Pharmacokinetic Parameters of anticoagulant therapies 1,2,3
| |Dabigatran |Warfarin |Enoxaparin |
|Prodrug |Yes |No |No |
|Time to Peak |2-3 hours |4 days |3-5 hours |
|Bioavailability |6.5% |100% |92% |
|Food-Peak Levels |Decreased |No Effect |No Effect |
|Food-AUC |No Effect |Vitamin K dependent |No Effect |
|Elimination half-life |2.5 days |14-17 hours |4.5 hours |
|Elimination altered in renal dysfunction |Yes |No |Yes |
|Elimination altered in Hepatic Dysfunction |No |Yes |No |
|Protein binding |25-30% |99.5% |80% bound-albumin |
Table 4: Comparative Doses of Anticoagulant Therapies 1,2,4,6
| |Dabigatran |Warfarin |Enoxaparin |
|Dosage Range |150mg daily to twice daily |2-10mg po daily |30mg sc every 12 hours to 1mg/kg sc every|
| | | |12 hours |
|Recommended initial dose |150mg po daily for VTE |5mg po daily |30mg sc every 12 hours for VTE |
| |prophylaxis | |prophylaxis |
| |150mg po daily for stroke | |1mg/kg sc every 12 hours for VTE |
| |prevention | |treatment |
|Maximum dose |300mg po bid |Based upon INR |Based upon Anti-factor Xa concentrations |
Table 5: Available Dosage Forms of Anticoagulant Therapies 1,2
| |Dabigatran |Warfarin |Enoxaparin |
|Strengths available|None |1mg, 2mg, 2.5mg, 3mg, 4mg, 5mg, 6mg, |30mg/0.3ml, 40mg/0.4ml, 60mg/0.6ml, |
| | |7.5mg, 10mg |80mg/0.8ml, 100mg/ml, 120mg/0.8ml, |
| | | |150mg/ml |
|Dosage form |Unknown |Scored tablets |Solutions for Injections |
POLICY AND PROCEDURE HIGHLIGHTS
Facility polices and procedures provide a guideline for medication administration and safety. The following data reflect excerpts from a Long Term Acute facility and guidelines. These guidelines are for review and not intended to guide your facility. Please refer to you own facilities policies and procedures for anticoagulation guidelines.
ANTICOAGULATION PROGRAM Policy and Procedure Example
❑ Evaluation of PT, INR, PTT and other relevant labs will be done.
❑ Assess patient for possible complications.
❑ Utilize standardized orders and written protocols for maintenance of warfarin, heparin (unfractionated) and all LMWH and the potential for drug interactions.
❑ The hospital will utilize only pre-packaged unit dose warfarin products.
❑ The hospital will utilize only one pre-mixed concentration of heparin infusion.
❑ The hospital will limit the number of concentrations of undiluted heparin injection.
❑ Warfarin – pharmacy will monitor all patients and have a baseline INR before therapy is initiated.
❑ Heparin (unfractionated) hospital will utilize programmable pumps for all I.V. heparin drips.
❑ LMWH – hospital will have a policy for monitoring.
DVT/PE Prophylaxis Orders
❑ Risk factors with point values
❑ Total risk factor score
o Patient at risk for bleeding or anticoagulation contraindication - intermittent pneumatic compression stockings
o Low risk – early ambulation
o Moderate/high risk – early ambulation, and one or more of the following (anticoagulant (Heparin or LMWH), TEDS, compression stockings)
o High risk - early ambulation, and one pharmacologic and on nonpharmacologic modality of the following (anticoagulant (Heparin or LMWH), TEDS, compression stockings)
COUMADIN (warfarin) Policy and Procedure Example
❑ Warfarin is given for patients with Acute Coronary Syndrome, Deep Vein Thrombosis, Pulmonary Embolism, atrial fibrillation and for prophylaxis of venous thrombosis or prosthethic mitral valve..
❑ Physician order as Coumadin per Pharmacy Protocol
❑ Baseline INR within 24 hours of initiation of 1st dose must be available to pharmacy before dispensing of warfarin.
❑ ACCP recommended INR therapeutic range:
o Most indications 2-3
o Prosthetic valves (high risk) 2.5 – 3.5
❑ Daily INR monitoring for warfarin initiation until therapeutic range has been maintained for at least 2 days, then 2 to 3 times per week for 1 – 2 weeks than every 4 weeks.
❑ Factors that interfere with warfarin:
o Diseases – liver, hyperthyroidism
o Drug interactions – metronidazole, trimethorprim/sulfamethoxaxole, cimetidine, omeprazole, amiodarone, rfampin, carbamazepine, aspirin, NSAIDs
❑ INR levels 10 – 20 – hold warfarin, Vitamin K 3 to 5 mg sq and recheck INR in 24 hours
❑ INR greater thean 20 – HOLD warfarin, Vitamin k 10 mg IV over 20 to 30 minutes and recheck INR every 6 hours. May repeat vitamin K prn every 12 hours. Plasma transfusion of prothrombin complex concentrate may be required.
❑ The Pharmacy Department will notify Food and Nutrition services for all patients receiving Warfarin Therapy.
❑ Warfarin dosing order form for adults
❑ Vitamin K Administration Order forms for reversal of warfarin anticoagulants.
LOW WEIGHT HEPARIN (LMWH) Policy and Procedure Example
❑ A baseline CBC and BMP will be obtained before therapy is initiated.
❑ Pharmacy will contact the physician for any patient receiving LMWH therapy if creatining clearance is less than 30 ml/min
❑ Enoxaparin sodium Adult Dosing/Indication Physician Order form
HEPARIN Policy and Procedure Example
❑ A provision of consistent Heparin Therapy for patients with Acute Coronary Syndrome, Deep Vein Thrombosis, Pulmonary Embolism, atrial fibrillation or prosthethic mitral valve..
❑ Physician order as “Heparin by Protocol”
❑ Modification to therapy will be made the RN based on the current PTT results.
❑ Specific orders may be written whenever the physician does not choose to use the protocol.
❑ Baseline CBC aPTT, PT/INR and platelet
❑ Dosing is based on patient’s IDEAL body weight (IBW)
o IBW female = 45.5 kg + (2.3 X inches over 5’)
o IBW male = 50 kg + (2.3 X inches over 5’)
❑ The rn will intitate heparin therapy with 25,000 units in 250 ml of either D5W or normal saline (1 ml = 100 unites)
❑ Monitoring
o aPTT 6 hours after initial heparin bolus
o aPTT 6 hours after any dosing change
❑ Adjust heparin by sliding scale until 2 consecutive aPTTs are therapeutic, then every 24 hours (readjust heparin as needed).
❑ Round off doses to nearest 100units/hour
❑ CBC and platelets every 3 days during treatment
❑ Notify primary care physician if platelets fall below 100.
❑ Target aPTT is 46-70 or 1.5-2.5 x baseline aPTT
❑ Dosages to be determined by IBW ranges.
Copyright Status
The majority of information at this packet is in the public domain. Unless stated otherwise, documents and files on NIH web servers can be freely downloaded and reproduced. Most documents are sponsored by the NIH; however, you may encounter documents that were sponsored along with private companies and other organizations. Accordingly, other parties may retain all rights to publish or reproduce these documents or to allow others to do so. Some documents available from this server may be protected under the United States and foreign copyright laws. Permission to reproduce may be required.
This is the end of the module: Please complete the evaluation and answer sheet and fax (951) 739-0378 or email to Educate100@
Key Medical Resources, Inc.
[pic]
-----------------------
Ca++
Ca++
End Result: Stabilized fibrin matrix or clot
Ca++
[pic]
Ca++
Ca++
Ca++
End Result: Stabilized fibrin matrix or clot
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- advances in cancer therapy
- advances in dental research
- advances in memory management
- advances in polymers
- advances in cancer treatment
- technology advances in cancer treatment
- recent advances in cancer treatment
- recent advances in cancer chemotherapy
- advances in therapy journal
- advances in therapy impact factor
- anticoagulation therapy for dvt
- anticoagulation therapy guidelines